PURPOSE: Low cholesterol levels and statin drugs may protect against prostate cancer with a worse prognosis. Their protective mechanism is unknown, but has been hypothesized to be related to cholesterol's role as a sex steroid hormone precursor. We evaluated whether serum testosterone and estradiol differ by cholesterol or cholesterol-lowering drug use. MATERIALS AND METHODS: Testosterone and estradiol were measured for 1,457 male participants in the Third National Health and Nutrition Examination Survey. We estimated multivariable-adjusted geometric mean hormone concentration by quintiles of cholesterol concentration and by cholesterol-lowering drugs use. RESULTS: Across quintiles of cholesterol, testosterone level did not differ (mean, 95% confidence interval (CI); Q1: 5.25, 5.02-5.49, Q5: 5.05, 4.76-5.37 ng/ml; p-trend = 0.32), whereas estradiol levels were lower (Q1: 38.7, 36.9-40.5; Q5: 33.1, 31.8-34.5 pg/ml; p-trend < 0.0001). Neither testosterone (no: 5.12, 4.94-5.30, yes: 4.91, 4.33-5.57 ng/ml, p = 0.57) nor estradiol (no: 35.9, 34.8-37.1; yes: 33.9, 29.4-39.2 pg/ml; p = 0.39) differed by cholesterol-lowering drugs use. CONCLUSION: Testosterone did not differ by cholesterol or cholesterol-lowering drug use. Estradiol was lower in men with higher cholesterol, but did not differ by cholesterol-lowering drug use. Our results suggest that the lower risk of advanced prostate cancer among statin users is not readily explained by a cholesterol-mediated effect of statins on sex hormone levels.
PURPOSE: Low cholesterol levels and statin drugs may protect against prostate cancer with a worse prognosis. Their protective mechanism is unknown, but has been hypothesized to be related to cholesterol's role as a sex steroid hormone precursor. We evaluated whether serum testosterone and estradiol differ by cholesterol or cholesterol-lowering drug use. MATERIALS AND METHODS:Testosterone and estradiol were measured for 1,457 male participants in the Third National Health and Nutrition Examination Survey. We estimated multivariable-adjusted geometric mean hormone concentration by quintiles of cholesterol concentration and by cholesterol-lowering drugs use. RESULTS: Across quintiles of cholesterol, testosterone level did not differ (mean, 95% confidence interval (CI); Q1: 5.25, 5.02-5.49, Q5: 5.05, 4.76-5.37 ng/ml; p-trend = 0.32), whereas estradiol levels were lower (Q1: 38.7, 36.9-40.5; Q5: 33.1, 31.8-34.5 pg/ml; p-trend < 0.0001). Neither testosterone (no: 5.12, 4.94-5.30, yes: 4.91, 4.33-5.57 ng/ml, p = 0.57) nor estradiol (no: 35.9, 34.8-37.1; yes: 33.9, 29.4-39.2 pg/ml; p = 0.39) differed by cholesterol-lowering drugs use. CONCLUSION:Testosterone did not differ by cholesterol or cholesterol-lowering drug use. Estradiol was lower in men with higher cholesterol, but did not differ by cholesterol-lowering drug use. Our results suggest that the lower risk of advanced prostate cancer among statin users is not readily explained by a cholesterol-mediated effect of statins on sex hormone levels.
Authors: W C Chumlea; S S Guo; R J Kuczmarski; K M Flegal; C L Johnson; S B Heymsfield; H C Lukaski; K Friedl; V S Hubbard Journal: Int J Obes Relat Metab Disord Date: 2002-12
Authors: Sabina Rinaldi; Annabelle Geay; Henri Déchaud; Carine Biessy; Anne Zeleniuch-Jacquotte; Arslan Akhmedkhanov; Roy E Shore; Elio Riboli; Paolo Toniolo; Rudolf Kaaks Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-10 Impact factor: 4.254
Authors: A S Dobs; H Schrott; M H Davidson; H Bays; E A Stein; D Kush; M Wu; Y Mitchel; R D Illingworth Journal: Metabolism Date: 2000-09 Impact factor: 8.694
Authors: Oludamilola W Oluleye; Richard A Kronmal; Aaron R Folsom; Dhananjay M Vaidya; Pamela Ouyang; Daniel A Duprez; Adrian S Dobs; Hirad Yarmohammadi; Suma H Konety Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Richard Davis; Kelly R Reveles; Sayed K Ali; Eric M Mortensen; Christopher R Frei; Ishak Mansi Journal: J Sex Med Date: 2014-11-25 Impact factor: 3.802
Authors: Edra London; Christina Tatsi; Steven J Soldin; Christopher A Wassif; Peter Backlund; David Ng; Leslie G Biesecker; Constantine A Stratakis Journal: Horm Metab Res Date: 2020-02-10 Impact factor: 2.936
Authors: David S Lopez; Danmeng Huang; Konstantinos K Tsilidis; Steven Canfield; Mohit Khera; Jacques G Baillargeon; Yong-Fang Kuo; M Kristen Peek; Elizabeth A Platz; Kyriakos Markides Journal: Cancer Causes Control Date: 2021-05-26 Impact factor: 2.506
Authors: Paavo V H Raittinen; Heimo Syvälä; Teuvo L J Tammela; Merja R Häkkinen; Pauliina Ilmonen; Seppo Auriola; Teemu J Murtola Journal: EBioMedicine Date: 2021-06-16 Impact factor: 8.143